Through our broad approach to drugging the immune system, we have generated a robust pipeline focused on bridging innate and adaptive immunity. Our differentiated antibodies and multispecifics effectively engage T cells and innate cells to promote tumor-specific activation or reverse immune suppression.
We are looking for strategic partners to help advance our pipeline of next-generation antibody therapeutics. We are also seeking discovery collaborations around our StitchMabs™ and common light chain discovery technologies.
Are you interested in collaborating with us? Contact firstname.lastname@example.org.